ALS/Speech

Pharma

The Breakthrough Prize Honors the C9orf72 Discovery Behind ALS and Dementia

Jul 1, 2026

•

2 min read

The Breakthrough Prize Honors the C9orf72 Discovery Behind ALS and Dementia

The 2026 Breakthrough Prize in Life Sciences recognized Rosa Rademakers and Bryan Traynor, whose 2011 finding named the most common genetic cause of ALS and frontotemporal dementia and opened the door to today's trials.

Aaron Rafferty

Healthcare

Neuralink Demonstrates Thought-to-Speech in ALS Patient Through VOICE Trial

Mar 28, 2026

•

4 min read

Neuralink Demonstrates Thought-to-Speech in ALS Patient Through VOICE Trial

Neuralink demonstrated thought-to-speech technology in ALS patient Kenneth Shock, the second participant in its VOICE clinical trial implanted in January 2026.

Aaron Rafferty

ALS/Speech

The Breakthrough Prize Honors the C9orf72 Discovery Behind ALS and Dementia

Neuralink Demonstrates Thought-to-Speech in ALS Patient Through VOICE Trial

WYDE Newsroom